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Mastectomy is an over-treatment
in patients with occult breast cancer
Janusz Piekarski, Piotr Pluta, Dariusz Nejc, Arkadiusz Jeziorski
B a c k g r o u n d.  In patients presenting with metastases of adenocarcinoma in axillary lymph nodes, and no evidence of
primary cancer on physical and radiological examination, the most probable source of metastases is an undetected microfocus
of breast cancer. Therefore, in such patients, "occult" breast cancer is diagnosed.
O b j e c t i v e.  Is mastectomy justified in such patients?
M a t e r i a l  a n d  m e t h o d s.  Twenty two patients with diagnosis of occult breast cancer operated on from January 1982 to
December 2002 in our Clinic composed the studied group. In 8 cases (36.4%) mastectomy was performed without the
diagnosis of primary focus in the breast. In one case surgical biopsy of the upper-outer quadrant of the breast revealed the
presence of cancer – the only case in the presented material of mastectomy performed after breast cancer diagnosis. Altogether,
mastectomy was performed in 9 women. In the remaining 13 cases, mastectomy was not performed.
R e s u l t s.  In 63.5% of women (5/8) who underwent mastectomy despite the lack of evidence of breast cancer, pathologic
examination did not reveal the presence of cancer. In 53.8% (7/13) of women in whom mastectomy was not performed, the
primary focus was identified in the breast during follow-up. Altogether, ipsilateral breast was identified as the source of
axillary metastases in 50.0% of women from the studied group. In 45.5% of women the primary focus remained undetected.
In one patient (4.5%), the primary focus of cancer was found 9 months after mastectomy in the ipsilateral kidney.
C o n c l u s i o n s.  In patients presenting with metastatic axillary lymphadenopathy and no evidence of breast cancer on
physical and radiological examination, mastectomy is a gross over-treatment.
Amputacja piersi u chorych na raka ukrytego piersi
jest post´powaniem zbyt rozleg∏ym
W s t ´ p.  U chorych z przerzutami raka gruczo∏owego do w´z∏ów ch∏onnych pachowych, u których nie stwierdzono raka na
drodze badania fizykalnego ani badaƒ obrazowych, najbardziej prawdopodobnym êród∏em tych przerzutów jest niewykryte
mikroognisko raka piersi. Dlatego te˝, u takich chorych rozpoznaje si´ raka "ukrytego" piersi.
C e l.  Czy wykonywanie amputacji piersi u takich chorych jest uzasadnione?
M a t e r i a ∏  i m e t o d y.  Grup´ badanà stanowi∏y 22 kobiety, u których rozpoznano raka „ukrytego” piersi, operowane
w Klinice od stycznia 1982 roku do grudnia 2002 roku. W 8 przypadkach (36,4%) wykonano amputacj´ piersi, choç nie
znaleziono przedoperacyjnie w piersi ogniska raka. U jednej chorej wykryto raka w piersi, wykonujàc biopsj´ kwadrantu górno-
bocznego piersi. By∏ to jedyny przypadek, w którym pierÊ amputowano, posiadajàc rozpoznanie raka. ¸àcznie amputacj´ piersi
wykonano u 9 kobiet. U pozosta∏ych 13 kobiet amputacji piersi nie wykonano.
W y n i k i.  U 63,5% kobiet (5/8) poddanych amputacji, pomimo braku rozpoznania raka, nie stwierdzono ogniska raka
w materiale pooperacyjnym. U 53,8% (7/13) kobiet, u których amputacji nie wykonano, ognisko pierwotne ujawni∏o si´ w piersi
w okresie obserwacji. ¸àcznie, rak piersi by∏ potwierdzonym êród∏em przerzutów u 50,0% kobiet z grupy badanej. U 45,5%
kobiet ognisko pierwotne nie zosta∏o zidentyfikowane. U jednej chorej (4,5%) ognisko pierwotne ujawni∏o si´ w nerce, 9
miesi´cy po amputacji piersi.
W n i o s k i.  U chorych z przerzutami raka gruczo∏owego do w´z∏ów ch∏onnych pachowych, u których nie stwierdza si´ raka na
drodze badania fizykalnego ani badaƒ obrazowych, amputacja piersi wydaje si´ post´powaniem zbyt rozleg∏ym.
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Introduction
In patients presenting with metastases of adenocarcinoma
in the axillary lymph nodes, and with no evidence of
primary cancer on physical and radiological examination,
the most probable source of metastases is an undetected
microfocus of breast cancer [1-3]. In such cases "occult"
breast cancer is diagnosed. The incidence of the entity
ranges form 0.3% to 1.0% of all breast cancers [2, 4-7].
However, the diagnosis of occult breast cancer does not
necessarily mean that the primary focus lies in the
ipsilateral breast. Literature reports indicate that lung,
thyroid, gastric, colorectal, pancreatic, kidney or ovarian
adenocarcinoma may be sources of axillary metastases
[7-10]. The primary focus may also be located in the
contralateral breast [11].
In patients with cytologically confirmed metastatic
axillary lymphadenopathy and no palpable tumor in the
breast, mammography and ultrasonography constitute
the first step of diagnostic workup. If no suspicious lesion
is depicted on mammography and sonography, a gross
therapeutic dilemma appears: should mastectomy be
performed or should the breast be spared? Axillary
lymphadenectomy may be performed as the next
diagnostic, and also the first therapeutic, procedure [3, 4,
12, 13]. The results of pathologic examination of removed
lymph nodes may indicate the breast as the most probable
source of metastases, however such a suggestion does not
resolve the problem. Currently, magnetic resonance
imaging is very helpful in the identification of otherwise
undetected breast cancers [8, 14-17]. However, the
method is quite new and not widely available in Poland.
Moreover, even magnetic resonance imaging does not
reveal the primary focus in every case of occult breast
cancer.
We have decided to present our experience with
occult breast cancer patients, in whom MRI was not
performed, in order to discuss the necessity of performing
mastectomy in such cases.
Objective
Is mastectomy justified in patients presenting with
metastatic axillary lymphadenopathy and with no evidence
of breast cancer on physical examination, mammography
and sonography?
Material and methods
The study group consisted of patients with the diagnosis of
occult breast cancer operated between January 1982 and
December 2002 at the Clinical Department of Surgical Oncology
of the Medical University of Lodz. Occult breast cancer was
diagnosed in patients presenting with metastatic axillary
lymphadenopathy and no evidence of breast cancer on physical
examination, mammography and sonography. No source of
metastases was found in other organs and systems in these
women, despite diagnostic workup.
Pa t i e n t s
Twenty two patients were retrospectively identified, mean age
58.1 years (range: 42–77 years; median: 60 years). In no patient
had cancer of the breast nor of other organs (incl. the
contralateral breast) been diagnosed before presentation. In
every case metastatic axillary lymphadenopathy was unilateral.
The metastatic tumor was diagnosed in the right axilla in 13
cases (59.1%) and in the left axilla in 9 cases (40.9%). The mean
diameter of the axillary tumor was 4.5 cm (range: 2-12 cm;
median 4 cm). In 3 patients (13.6%) the axillary tumors were
fixed to adjacent structures (N2). In the remaining 19 cases
(86.4%), the tumors were movable. In each case cytological
examination confirmed the malignant character of the axillary
tumor.
S u r g i c a l  t r e a t m e n t
In 2 patients (9.1%) modified radical mastectomy (acc. to
Madden) was performed. In 4 patients (18.2%) axillary
lymphadenectomy with surgical biopsy of the upper-outer
quadrant of ipsilateral breast was done. In 12 patients (54.5%)
surgical treatment started with axillary lymphadenectomy only.
After pathologic examination of the axillary specimen, indicating
breast as the most probable source of metastases, in 6 of these 12
women, modified radical mastectomy (acc. to Madden) was
performed. In 4 women (18.2%) only an incisional biopsy of
the axillary tumor was done, as it was impossible to resect the
tumor radically. Altogether, in 8 cases (36.4%) mastectomy was
performed without the diagnosis of a primary focus in the breast.
Details of treatment (locoregional and systemic) are presented in
Table I.
A n a l y s i s
We assessed the proportion of women in whom mastectomy or
surgical biopsy of the upper-outer quadrant of the breast were
performed with the diagnosis of breast cancer and of those in
whose case the primary focus was not found. We also present the
number of cases in which the primary focus was found in the
breast or other organs during follow-up and in how many cases
the primary focus remained unknown.
Results
Among 8 women who had undergone mastectomy,
detailed pathologic examination revealed the presence
of cancer in 3 cases (37.5%). In 5 cases the primary focus
was not found in the post-mastectomy specimens (5/8;
62.5%).
Among 4 women in whom surgical biopsy of the
upper-outer quadrant of the ipsilateral breast was
performed the primary focus was found in 1 case. In 3
cases, cancer was not found in the resected tissue.
Altogether, on pathologic examination the primary focus
was found in the breasts of 4 women.
Therefore, the search for the primary focus
continued in 18 women during the follow-up period. The
subgroup consisted of 5 women after mastectomy, in
whom no primary focus was found in the breast, and of 13
women who did not undergo mastectomy.
Mean duration of follow-up was 36.9 months (range:
1 – 153 months; median: 21 months). During follow-up
the primary focus was found in the breast in 7 of 13
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women who did not undergo mastectomy (53.8%). In 1
case, the primary focus was identified in the kidney 9
months after the mastectomy had been performed. In 10
women the primary focus was not found during follow-up.
Altogether, in 11 of the 22 studied women (50.0%)
the primary focus was in the ipsilateral breast, in 1 woman
the primary focus was in the kidney. In the remaining 10
women, the primary focus remained unknown.
Discussion
In 63.5% of women who underwent mastectomy despite
the lack of evidence of breast cancer on physical and
radiological examination, pathologic examination did not
reveal the presence of cancer. Moreover, in one of these
patients, the primary focus of cancer was found 9 months
later in the ipsilateral kidney. On the other hand, in
53.8% of women in whom mastectomy was not
performed, the primary focus was identified in the breast
during follow-up. Altogether, the breast was identified
as a source of metastases in 50.0% of women from the
studied group. It means that in half of the studied women
mastectomy was unnecessary. We think that a 50%
probability of presence of cancer in the breast does not
justify its amputation. This is gross and unacceptable
over-treatment.
However, it should be noted, that even detailed
pathologic examination of the postoperative specimen
may not reveal cancer if the focus is very small. Therefore,
the percentage of unnecessarily performed mastectomies
in the studied group may be somewhat lower. Moreover,
the duration of follow-up in our study is not very long. It
means than in some women the primary focus might have
appeared in the breast or in other organs later, after the
end of our follow-up period. The fact that the primary
focus remained undetected in some women, may also be
the result of adjuvant treatment introduced in these
patients.
Our identification rate of the primary focus in post-
mastectomy specimens is lower than values reported by
other authors [2, 3, 5]. They report finding the primary
focus in 49% – 75% of the removed breasts [2, 3, 5, 6].
An analysis of both our material and of the literature
data has forced us to conclude that in occult breast cancer
mastectomy is, to an extent, blindfold surgery, and should
not be performed. Many authors claim that mastectomy
was the treatment of choice for occult breast cancer
patients. However, these papers were published in the
1950s-1970s [1, 6, 7, 18-20]. In the literature published
in the 1980s and the 1990s, the majority of authors opt
against mastectomy, suggesting whole breast irradiation
and systemic treatment in these patients [5, 8, 21, 22].
Current literature indicates that the sensitivity of
magnetic resonance imaging is twofold higher than the
sensitivity of mammography [23-26] and can reveal the
presence of a primary focus in breast in a vast majority of
patients with occult breast cancer [15-17]. In the
remaining cases the primary focus may be situated in
other organs.
To summarise, it is mandatory to perform magnetic
resonance imaging in each case of occult breast cancer.
The treatment of such patients should not be started
before magnetic resonance imaging. The method is
available in Poland, and its costs are refunded.
Conclusions
In patients presenting with metastatic axillary
lymphadenopathy and no evidence of breast cancer on
physical examination, mammography and sonography,
mastectomy is a gross over-treatment.
Janusz Piekarski MD, Ph
Clinical Department of Surgical Oncology
Medical University of ¸ódê
Paderewskiego 4
93-509 ¸ódê
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